These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11975794)

  • 61. Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.
    Mouillac B; Mendre C
    Handb Exp Pharmacol; 2018; 245():63-83. PubMed ID: 28939971
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1).
    Schrier RW
    N Engl J Med; 1988 Oct; 319(16):1065-72. PubMed ID: 3050518
    [No Abstract]   [Full Text] [Related]  

  • 63. [Vasopressin type 2 receptor mutations in congenital diabetes insipidus].
    Tsukaguchi H; Matsubara H; Inada M
    Nihon Rinsho; 1998 Jul; 56(7):1848-55. PubMed ID: 9702064
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
    Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
    [TBL] [Abstract][Full Text] [Related]  

  • 65. V2R mutations and nephrogenic diabetes insipidus.
    Bichet DG
    Prog Mol Biol Transl Sci; 2009; 89():15-29. PubMed ID: 20374732
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Molecular mechanisms and drug development in aquaporin water channel diseases: molecular mechanism of water channel aquaporin-2 trafficking.
    Noda Y; Sasaki S
    J Pharmacol Sci; 2004 Nov; 96(3):249-54. PubMed ID: 15539762
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Aquaporin-2, a vasopressin-sensitive water channel, and nephrogenic diabetes insipidus.
    Kuwahara M
    Intern Med; 1998 Feb; 37(2):215-7. PubMed ID: 9550615
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra).
    Bouley R; Pastor-Soler N; Cohen O; McLaughlin M; Breton S; Brown D
    Am J Physiol Renal Physiol; 2005 Jun; 288(6):F1103-12. PubMed ID: 15644488
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vasopressin receptors.
    Birnbaumer M
    Trends Endocrinol Metab; 2000 Dec; 11(10):406-10. PubMed ID: 11091117
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term regulation of aquaporins in the kidney.
    Marples D; Frøkiaer J; Nielsen S
    Am J Physiol; 1999 Mar; 276(3):F331-9. PubMed ID: 10070156
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vasopressin receptor mutations and nephrogenic diabetes insipidus.
    Birnbaumer M
    Arch Med Res; 1999; 30(6):465-74. PubMed ID: 10714359
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Hereditary nephrogenic diabetes insipidus].
    Morin D; Ala Y; Dumas R
    Arch Pediatr; 1995 Jun; 2(6):560-7. PubMed ID: 7640759
    [TBL] [Abstract][Full Text] [Related]  

  • 73. V2 vasopressin receptor deficiency causes changes in expression and function of renal and hypothalamic components involved in electrolyte and water homeostasis.
    Schliebe N; Strotmann R; Busse K; Mitschke D; Biebermann H; Schomburg L; Köhrle J; Bär J; Römpler H; Wess J; Schöneberg T; Sangkuhl K
    Am J Physiol Renal Physiol; 2008 Oct; 295(4):F1177-90. PubMed ID: 18715941
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Vasopressin V2-receptor antagonists: panaceas for hyponatremia?
    Kitiyakara C; Wilcox CS
    Curr Opin Nephrol Hypertens; 1997 Sep; 6(5):461-7. PubMed ID: 9327205
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Decreased vasopressin-mediated renal water reabsorption in rats with compensated liver cirrhosis.
    Jonassen TE; Nielsen S; Christensen S; Petersen JS
    Am J Physiol; 1998 Aug; 275(2):F216-25. PubMed ID: 9691010
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vasopressin receptor antagonism--a therapeutic option in heart failure and hypertension.
    Burrell LM; Risvanis J; Johnston CI; Naitoh M; Balding LC
    Exp Physiol; 2000 Mar; 85 Spec No():259S-265S. PubMed ID: 10795930
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Renal aquaporins and water balance disorders.
    Kortenoeven ML; Fenton RA
    Biochim Biophys Acta; 2014 May; 1840(5):1533-49. PubMed ID: 24342488
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans.
    Bankir L; Fernandes S; Bardoux P; Bouby N; Bichet DG
    J Am Soc Nephrol; 2005 Jul; 16(7):1920-8. PubMed ID: 15888562
    [TBL] [Abstract][Full Text] [Related]  

  • 79. BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats.
    Kazama I; Hatano R; Michimata M; Suzuki K; Arata T; Suzuki M; Miyama N; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
    Kidney Int; 2005 May; 67(5):1855-67. PubMed ID: 15840033
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Molecular basis and clinical features of nephrogenic diabetes insipidus.
    Schulz A; Römpler H; Mitschke D; Thor D; Schliebe N; Hermsdorf T; Strotmann R; Sangkuhl K; Schöneberg T
    Expert Rev Endocrinol Metab; 2006 Nov; 1(6):727-741. PubMed ID: 30754158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.